Hepatitis C Therapy: Other Players in the Game

Joseph Ahn, Steven L. Flamm

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Therapies in addition to the direct-acting antiviral agents (DAA) under evaluation for chronic hepatitis C include host targets such as cyclophilin inhibitors and immunomodulators. Both passive and therapeutic vaccines hold promise for the future. Although the numbers of drug categories and individual agents are increasing, only a handful of the non-DAAs seem to be ready to move on to phase III trials. New interferon agents are in development, and ribavirin variants are still under consideration. The role of the other players in the overall armamentarium against hepatitis C virus is still evolving.

Original languageEnglish (US)
Pages (from-to)641-656
Number of pages16
JournalClinics in Liver Disease
Volume15
Issue number3
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Hepatitis C
Cyclophilins
Ribavirin
Immunologic Factors
Chronic Hepatitis C
Hepacivirus
Interferons
Antiviral Agents
Vaccines
Therapeutics
Pharmaceutical Preparations

Keywords

  • Cyclophilin inhibitor
  • Hepatitis C
  • Therapeutic vaccine
  • Thiazolide
  • TLR agonist

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatitis C Therapy : Other Players in the Game. / Ahn, Joseph; Flamm, Steven L.

In: Clinics in Liver Disease, Vol. 15, No. 3, 08.2011, p. 641-656.

Research output: Contribution to journalArticle

Ahn, Joseph ; Flamm, Steven L. / Hepatitis C Therapy : Other Players in the Game. In: Clinics in Liver Disease. 2011 ; Vol. 15, No. 3. pp. 641-656.
@article{60baafe18d5948c4a1776088a51ccf37,
title = "Hepatitis C Therapy: Other Players in the Game",
abstract = "Therapies in addition to the direct-acting antiviral agents (DAA) under evaluation for chronic hepatitis C include host targets such as cyclophilin inhibitors and immunomodulators. Both passive and therapeutic vaccines hold promise for the future. Although the numbers of drug categories and individual agents are increasing, only a handful of the non-DAAs seem to be ready to move on to phase III trials. New interferon agents are in development, and ribavirin variants are still under consideration. The role of the other players in the overall armamentarium against hepatitis C virus is still evolving.",
keywords = "Cyclophilin inhibitor, Hepatitis C, Therapeutic vaccine, Thiazolide, TLR agonist",
author = "Joseph Ahn and Flamm, {Steven L.}",
year = "2011",
month = "8",
doi = "10.1016/j.cld.2011.05.008",
language = "English (US)",
volume = "15",
pages = "641--656",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Hepatitis C Therapy

T2 - Other Players in the Game

AU - Ahn, Joseph

AU - Flamm, Steven L.

PY - 2011/8

Y1 - 2011/8

N2 - Therapies in addition to the direct-acting antiviral agents (DAA) under evaluation for chronic hepatitis C include host targets such as cyclophilin inhibitors and immunomodulators. Both passive and therapeutic vaccines hold promise for the future. Although the numbers of drug categories and individual agents are increasing, only a handful of the non-DAAs seem to be ready to move on to phase III trials. New interferon agents are in development, and ribavirin variants are still under consideration. The role of the other players in the overall armamentarium against hepatitis C virus is still evolving.

AB - Therapies in addition to the direct-acting antiviral agents (DAA) under evaluation for chronic hepatitis C include host targets such as cyclophilin inhibitors and immunomodulators. Both passive and therapeutic vaccines hold promise for the future. Although the numbers of drug categories and individual agents are increasing, only a handful of the non-DAAs seem to be ready to move on to phase III trials. New interferon agents are in development, and ribavirin variants are still under consideration. The role of the other players in the overall armamentarium against hepatitis C virus is still evolving.

KW - Cyclophilin inhibitor

KW - Hepatitis C

KW - Therapeutic vaccine

KW - Thiazolide

KW - TLR agonist

UR - http://www.scopus.com/inward/record.url?scp=80051943544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051943544&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2011.05.008

DO - 10.1016/j.cld.2011.05.008

M3 - Article

C2 - 21867942

AN - SCOPUS:80051943544

VL - 15

SP - 641

EP - 656

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -